CX3CL1 and interstitial lung disease: CX3CL1 was in univariable analyses significantly associated with the primary endpoint ILD progression (OR 1.24, 95% CI 1.08–1.41, p = 0.002), as well as age at onset (OR 1.05, 95% CI 1.03–1.07, p<0.001), mRSS (OR 1.03, 95% CI 1.00–1.07, p = 0.039), and baseline DLCO% (OR 0.98, 95% CI 0.97–0.99, p = 0.025).